GLAXO U.S. SALES GROWTH SLOWS TO 3% FOR SECOND HALF OF 1994; U.S. SALES TOTAL $1.91 BIL.; DISCOUNTING REDUCES WORLDWIDE ZANTAC SALES 4% TO $1.78 BIL.
Executive Summary
Glaxo's U.S. sales rose 3% for the six months ended Dec. 31 compared to the year-earlier period as U.S. sales totaled [pound]1.22 bil. ($1.91 bil.), according to interim results announced Feb. 7